Form 8-K - Current report:
SEC Accession No. 0001558370-21-010969
Filing Date
2021-08-09
Accepted
2021-08-09 16:08:28
Documents
14
Period of Report
2021-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20210809x8k.htm   iXBRL 8-K 35363
2 EX-99.1 adap-20210809xex99d1.htm EX-99.1 317538
3 GRAPHIC adap-20210809xex99d1001.jpg GRAPHIC 7110
  Complete submission text file 0001558370-21-010969.txt   503293

Data Files

Seq Description Document Type Size
4 EX-101.SCH adap-20210809.xsd EX-101.SCH 3216
5 EX-101.LAB adap-20210809_lab.xml EX-101.LAB 16114
6 EX-101.PRE adap-20210809_pre.xml EX-101.PRE 10933
7 EXTRACTED XBRL INSTANCE DOCUMENT adap-20210809x8k_htm.xml XML 4874
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 211156518
SIC: 2836 Biological Products, (No Diagnostic Substances)